New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2015
17:21 EDTFDXFedEx backs FY16 $4.6B capital spending view
On July 21, FedEx Corporationís wholly owned subsidiary Federal Express Corporation and The Boeing Company entered into Supplemental Agreement No. 6 to Purchase Agreement Number 3712 dated as of December 14, 2011, between Boeing and FedEx Express related to Boeing 767-300 Freighter aircraft. In the Supplemental Agreement, FedEx Express agreed to purchase 50 additional B767F aircraft from Boeing. Four of the 50 additional firm-order B767F aircraft purchases are conditioned upon there being no event that causes FedEx Express or its employees not to be covered by the Railway Labor Act of 1926, as amended. The 50 additional firm-order B767F aircraft are expected to be delivered from fiscal 2018 through fiscal 2023 and will enable FedEx Express to continue to improve the efficiency and reliability of its aircraft fleet. FedEx Express now has a total of 106 firm orders for B767F aircraft from Boeing through fiscal 2023. In the Supplemental Agreement, FedEx Express also acquired options to purchase an additional 15 B767F aircraft. As a result, FedEx Express now has options to purchase a total of 50 B767F aircraft from Boeing. Expected capital spending for FedEx Corporation for fiscal 2016 remains at approximately $4.6 billion. The impact to FedEx Corporationís capital spending in fiscal 2017 from this new B767F aircraft order is expected to be immaterial.
09:33 EDTLLYEli Lilly weakness creates buying opportunity, says Argus
Subscribe for More Information
July 23, 2015
14:34 EDTFDXFedEx CEO says would do business in Iran if permitted
Subscribe for More Information
14:30 EDTFDXFedEx CEO feels Fed shoud raise rates this year
Subscribe for More Information
10:08 EDTLLYOptions with decreasing implied volatility
Subscribe for More Information
08:43 EDTLLYEli Lilly Alzheimer's data positive, says SunTrust
Subscribe for More Information
06:48 EDTLLYEli Lilly up 5.5% after reporting Q2 results, raising FY15 guidance
06:37 EDTLLYEli Lilly expands San Diego biotechnology center
Subscribe for More Information
06:33 EDTLLYEli Lilly raises FY15 EPS view to $3.20-$3.30 from $3.10-$3.20, consensus $3.18
Narrows FY15 revenue guidance to $19.7B-$20B from $19.5B-$20B, consensus $19.8B.
06:30 EDTLLYEli Lilly reports Q2 adjusted EPS 90c, consensus 74c
Subscribe for More Information
July 22, 2015
15:26 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
10:59 EDTLLYBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:05 EDTLLYEli Lilly gaps down, retraces, levels to watch
Subscribe for More Information
08:40 EDTLLYEli Lilly July weekly volatility elevated into Q2 and Alzheimer's drug data
Subscribe for More Information
07:18 EDTLLYEli Lilly drops 3% to $83 after reporting Alzheimer's drug data
Subscribe for More Information
07:06 EDTLLYEli Lilly's solanezumab for Alzheimer's supports 'delayed-start' use
Subscribe for More Information
July 21, 2015
17:41 EDTFDXFedEx to acquire fifty additional 767-300F aircraft from Boeing
Subscribe for More Information
July 20, 2015
07:32 EDTLLYAlzheimer's Association to hold a conference
Subscribe for More Information
July 17, 2015
11:16 EDTFDXFedEx spikes higher, levels to watch
Subscribe for More Information
11:07 EDTFDXRumor: FedEx moves up on activist investor speculation
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use